Loxo Oncology, Inc. (LOXO)

Oncology Corporate Profile

Stock Performance

44.7200
1.2900

HQ Location

1 Landmark Square, Suite 1122
Stamford, CT 06901

Company Description

Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, MD. Loxo Oncology is committed to bringing targeted cancer therapies rapidly into the clinic that have an opportunity for clinical success in genetically defined patient populations

Website: http://www.loxooncology.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Loxo-101tropomyocin receptor kinase A (TrkA) inhibitorVarious cancer typesII
Loxo-101tropomyocin receptor kinase A (TrkA) inhibitorSarcomaI

View additional information on product candidates here »

Source


http://www.loxooncology.com

Recent News Headlines

Loxo Oncology Announces Larotrectinib Pan-TRK IHC Companion Diagnostic Collaboration with Ventana Medical Systems, Inc., a member of the Roche Group

3/20/2017 10:04 am

[GlobeNewswire] - STAMFORD, Conn., March 20, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced ...

Loxo reports 4Q loss

3/7/2017 11:05 am

Loxo reports 4Q loss

3/7/2017 11:05 am

Loxo Oncology Reports Fourth Quarter and Year-End 2016 Financial Results

3/7/2017 11:04 am

[GlobeNewswire] - STAMFORD, Conn., March 07, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today reported ...

Loxo Oncology to Present at Cowen and Company 37th Annual Health Care Conference

3/1/2017 11:04 am

[GlobeNewswire] - STAMFORD, Conn., March 01, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced ...

Loxo Oncology to Announce Fourth Quarter and Year-End 2016 Financial Results

2/28/2017 11:04 am

[GlobeNewswire] - STAMFORD, Conn., Feb. 28, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial ...

Loxo Oncology Announces Completion of Clinical Trial Enrollment for Larotrectinib NDA Primary Efficacy Analysis

2/21/2017 11:04 am

[GlobeNewswire] - STAMFORD, Conn., Feb. 21, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced ...

Purcell Julie & Lefkowitz LLP is Investigating Loxo Oncology, Inc. for Potential Breaches of Fiduciary Duty by its Board of Directors

2/8/2017 10:04 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 8, 2017 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary ...

Loxo Oncology Announces the Closing of its Follow-On Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

1/10/2017 09:03 pm

[GlobeNewswire] - STAMFORD, Conn., Jan. 10, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced ...

Loxo Oncology Prices Follow-On Offering of Common Stock

1/5/2017 12:03 pm

[at noodls] - STAMFORD, Conn., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically ...

Loxo Oncology Prices Follow-On Offering of Common Stock

1/5/2017 11:04 am

[GlobeNewswire] - STAMFORD, Conn., Jan. 05, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced ...

Loxo Oncology Announces Proposed Public Offering of Common Stock

1/4/2017 09:03 pm

[at noodls] - STAMFORD, Conn., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically ...

Loxo Oncology Announces Proposed Public Offering of Common Stock

1/4/2017 09:00 pm

[GlobeNewswire] - STAMFORD, Conn., Jan. 04, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, announced today ...